Editing Pfizer (section)

=== 2010–2020: Further discoveries and acquisitions ===
[[File:235 E42 St 2025 jeh.jpg|thumb|Former headquarters on 42nd Street]]
[[File:Pfizer World Headquarters (51921996957).jpg|thumb|Entrance to former Pfizer World Headquarters building (1961–2023)]]
In 2010, [[Ian Read]] was named [[chief executive officer]] of the company.<ref>{{Cite press release |url=https://www.businesswire.com/news/home/20190927005072/en/Ian-Read-to-Retire-as-Executive-Chairman-of-Pfizer%E2%80%99s-Board-of-Directors-Chief-Executive-Officer-Dr.-Albert-Bourla-Named-Chairman |title=Ian Read to Retire as Executive Chairman of Pfizer's Board of Directors; Chief Executive Officer Dr. Albert Bourla Named Chairman |publisher=[[Business Wire]] |date=September 27, 2019}}</ref>

In February 2011, Pfizer announced the closure of its UK research and development facility (formerly also a manufacturing plant) in [[Sandwich, Kent]], which at the time employed 2,400 people.<ref>{{Cite news |url=https://www.bbc.co.uk/news/business-12335801 |title=Pfizer to close UK research site |work=[[BBC News]] |date=February 1, 2011}}</ref> In March 2011, Pfizer acquired [[King Pharmaceuticals]] for $3.6{{nbsp}}billion in cash. King produced emergency injectables such as the [[EpiPen]].<ref>{{Cite news |url=https://www.modernhealthcare.com/article/20110301/NEWS/303019922/pfizer-closes-king-pharmaceuticals-acquisition |title=Pfizer closes King Pharmaceuticals acquisition |first=Maureen |last=Mckinney |work=[[Modern Healthcare]] |date=March 1, 2011}}</ref>

On September 4, 2012, the FDA approved [[bosutinib]] (Bosulif) for [[chronic myelogenous leukemia]] (CML), a rare type of [[leukemia]] and a blood and [[bone marrow]] disease that affects primarily older adults.<ref>{{Cite news |url=https://www.reuters.com/article/us-pfizer-leukemia/fda-approves-pfizer-leukemia-drug-idUSBRE88314720120904 |title=FDA approves Pfizer leukemia drug |first=Anna |last=Yukhananov |work=[[Reuters]] |date=September 4, 2012}}</ref> In November 2012, Pfizer received approval from the [[Food and Drug Administration]] for Xeljanz, a [[tofacitinib]], for [[rheumatoid arthritis]] and [[ulcerative colitis]].<ref>{{Cite web |url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203214orig1s000toc.cfm |title=Drug Approval Package |publisher=[[Food and Drug Administration]]}}</ref> The drug had sales of $1.77{{nbsp}}billion in 2018, and in January 2019, it was the top drug in the United States for [[direct-to-consumer advertising]], passing [[adalimumab]] (Humira).<ref>{{Cite magazine |title=Pfizer switches RA patients to lower dose of fast-growing Xeljanz as safety issues arise in postmarketing study |url=https://www.fiercepharma.com/pharma/postmarketing-study-pfizer-switches-ra-patients-to-lower-xeljanz-dose-safety-concerns |magazine=Fierce Pharma |first=Eric |last=Sagonowsky |date=February 20, 2019}}</ref> In 2023, the Institute for Clinical and Economic Review (ICER) identified Xeljanz (tofacitinib) as one of five high-expenditure drugs that experienced significant net price increases without new clinical evidence to justify the hikes. Specifically, Xeljanz's wholesale acquisition cost rose by 6%, leading to an additional $72 million in costs to U.S. payers.<ref>{{Cite web |title=Institute for Clinical and Economic Review Announces Most Significant Drug-Price Hikes Unsupported by New Clinical Evidence in US |url=https://icer.org/news-insights/press-releases/icer-announces-most-significant-drug-price-hikes-unsupported-by-new-clinical-evidence-in-us/?mkt_tok=NjM4LVBYUi0zMTgAAAGYMxe5Fv3mzhJbiVnr0V4g2FUAcS3PgZOZSYRvQcW3_VFPXIet0TCD7bWAyVVeW2Q62e3AynO8rDpP8sIoIbs_qux8kQcMBBD4cDSe3Q |access-date=2025-02-06 |website=ICER |language=en-US}}</ref>

On February 1, 2013, [[Zoetis]], the Agriculture Division of Pfizer and later Pfizer Animal Health, became a [[public company]] via an [[initial public offering]], raising $2.2{{nbsp}}billion.<ref>{{Cite press release |title=Zoetis™ Files IPO Registration Statement |url=https://www.zoetisus.com/news-and-media/zoetis-files-ipo-registration-statement.aspx |publisher=[[Business Wire]] |date=August 13, 2012}}</ref><ref>{{Cite news |url=https://dealbook.nytimes.com/2013/02/01/shares-of-zoetis-surge-on-debut/ |last=J. de la Merced |first=Michael |title=Shares of Zoetis Surge on Debut |work=[[The New York Times]] |date=February 1, 2013 |url-access=limited}}</ref><ref>{{Cite news |title=Zoetis Raises $2.2 Billion in IPO |url=https://www.wsj.com/articles/SB10001424127887323701904578276530830057770 |last=Dieterich |first=Chris |work=[[The Wall Street Journal]] |date=January 31, 2013 |url-access=subscription}}</ref><ref>{{Cite news |url=https://www.cbsnews.com/news/shares-of-animal-health-company-zoetis-soar-in-ipo/ |title=Shares of animal health company Zoetis soar in IPO |agency=[[Associated Press]] |publisher=[[CBS News]] |date=February 1, 2013}}</ref> Later in 2013, Pfizer completed the [[corporate spin-off]] of its remaining stake in [[Zoetis]].<ref>{{Cite news |url=https://www.wsj.com/articles/SB10001424127887323975004578498994013821124 |title=Pfizer to Spin Off Remaining Zoetis Stake |first=Peter |last=Loftus |work=[[The Wall Street Journal]] |date=May 22, 2013}}</ref><ref>{{Cite news |url=https://www.reuters.com/article/us-pfizer-zoetis/pfizer-to-spin-off-zoetis-stake-to-shareholders-idUSBRE94L0JB20130522 |title=Pfizer to spin off Zoetis stake to shareholders |first1=Caroline |last1=Humer |first2=Ransdell |last2=Pierson |work=[[Reuters]] |date=May 22, 2013}}</ref>

In September 2014, the company acquired Innopharma for $225{{nbsp}}million, plus up to $135{{nbsp}}million in milestone payments, in a deal that expanded Pfizer's range of generic and injectable drugs.<ref>{{Cite magazine |url=https://www.fiercepharma.com/pharma/pfizer-completes-acquisition-of-innopharma |title=Pfizer Completes Acquisition Of InnoPharma |first=Emily |last=Wasserman |magazine=Fierce Pharma |date=September 29, 2014}}</ref><ref>{{Cite news |title=Pfizer to Acquire InnoPharma for Up to $360M |url=https://www.genengnews.com/news/pfizer-to-acquire-innopharma-for-up-to-360m/ |website=genengnews.com |date=July 16, 2014}}</ref>

On January 5, 2015, the company announced it would acquire a controlling interest in Redvax, expanding its vaccine portfolio targeting human [[cytomegalovirus]].<ref>{{Cite news |title=Pfizer Buys Redvax, Boosting Vaccine Portfolio |url=https://www.genengnews.com/topics/drug-discovery/pfizer-buys-redvax-boosting-vaccine-portfolio/ |website=genengnews.com |date=January 5, 2015}}</ref> In February 2015, the company received approval from the [[Food and Drug Administration]] for [[palbociclib]] (Ibrance) for treatment of certain types of [[breast cancer]].<ref>{{cite journal|display-authors=3 |last1=Beaver |first1=Julia A. |last2=Amiri-Kordestani |first2=Laleh |last3=Charlab |first3=Rosane |last4=Chen |first4=Wei |last5=Palmby |first5=Todd |last6=Tilley |first6=Amy |last7=Zirkelbach |first7=Jeanne Fourie |last8=Yu |first8=Jingyu |last9=Liu |first9=Qi |last10=Zhao |first10=Liang |last11=Crich |first11=Joyce |last12=Chen |first12=Xiao Hong |last13=Hughes |first13=Minerva |last14=Bloomquist |first14=Erik |last15=Tang |first15=Shenghui |last16=Sridhara |first16=Rajeshwari |last17=Kluetz |first17=Paul G. |last18=Kim |first18=Geoffrey |last19=Ibrahim |first19=Amna |last20=Pazdur |first20=Richard |last21=Cortazar |first21=Patricia |title=FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer |journal=Clinical Cancer Research |date=1 November 2015 |volume=21 |issue=21 |pages=4760–4766 |doi=10.1158/1078-0432.CCR-15-1185 |pmid=26324739 |s2cid=24762535 |doi-access=free}}</ref><ref>{{Cite web |url=https://www.fda.gov/drugs/resources-information-approved-drugs/palbociclib-ibrance |title=Palbociclib (IBRANCE) |date=February 9, 2019 |publisher=[[Food and Drug Administration]]}}</ref> In March 2015, the company announced it would restart its collaboration with [[Eli Lilly and Company]] surrounding the [[Phase III trial]] of [[Tanezumab]].<ref>{{Cite news |title=Pfizer, Lilly to Resume Phase III Tanezumab Clinical Program |url=https://www.genengnews.com/topics/drug-discovery/pfizer-lilly-to-resume-phase-iii-tanezumab-clinical-program/ |website=genengnews.com |date=March 23, 2015}}</ref> In May 2015, Pfizer and a [[Bar-Ilan University]] laboratory announced a partnership based on the development of medical [[DNA nanotechnology]].<ref>{{Cite news |last=Gali |first=Weinreb |title=Pfizer to collaborate on Bar-Ilan DNA robots |work=[[Globes (newspaper)|Globes]] |url=https://en.globes.co.il/en/article-pfizer-to-collaborate-on-bar-ilan-dna-robots-1001036703 |date=May 14, 2015}}</ref> In June 2015, the company acquired Nimenrix and Mencevax, [[meningococcal vaccine]]s, from GlaxoSmithKline for around $130{{nbsp}}million.<ref>{{Cite news |title=Pfizer Buys Two GSK Meningitis Vaccines for $130M |url=https://www.genengnews.com/topics/drug-discovery/pfizer-buys-two-gsk-meningitis-vaccines-for-130m/ |website=genengnews.com |date=June 22, 2015}}</ref> In September 2015, Pfizer acquired [[Hospira]] for $17{{nbsp}}billion, including the assumption of debt.<ref>{{Cite press release |url=https://www.businesswire.com/news/home/20150903005752/en/Pfizer-Completes-Acquisition-of-Hospira |title=Pfizer Completes Acquisition of Hospira |publisher=Pfizer |via=[[Business Wire]] |date=September 3, 2015}}</ref><ref>{{Cite news |url=https://www.thepharmaletter.com/article/pfizer-completes-17-billion-hospira-acquisition |title=Pfizer completes $17-billion Hospira acquisition |work=[[The Pharma Letter]] |date=September 4, 2015}}</ref><ref>{{Cite news |first1=David |last1=Gelles |first2=Katie |last2=Thomas |title=Pfizer Bets $15 Billion on New Class of Generic Drugs |url=https://dealbook.nytimes.com/2015/02/05/pfizer-to-buy-hospira-a-drug-maker-for-15-2-billion-in-cash |work=[[The New York Times]] |date=February 5, 2015 |url-access=limited}}</ref><ref>{{Cite web |title=8-K |url=https://www.sec.gov/Archives/edgar/data/78003/000119312515037588/d866443d8k.htm |publisher=[[U.S. Securities and Exchange Commission]] |date=February 6, 2015}}</ref><ref>{{Cite press release |title=Pfizer to Acquire Hospira |url=https://www.pfizer.com/news/press-release/press-release-detail/pfizer_to_acquire_hospira |work=Pfizer |access-date=May 1, 2021 |archive-date=April 26, 2021 |archive-url=https://web.archive.org/web/20210426025941/https://www.pfizer.com/news/press-release/press-release-detail/pfizer_to_acquire_hospira |url-status=dead }}</ref><ref>{{Cite news |last=Neilan |first=Catherine |title=Pfizer, Hospira share prices to soar after $17bn deal announced |url=https://www.cityam.com/pfizer-hospira-share-prices-soar-after-17bn-deal-announced/ |work=[[City A.M.]] |date=February 5, 2015}}</ref> [[Hospira]] was the largest producer of generic injectable pharmaceuticals in the world.<ref>{{Cite news |title=US-based Hospira to buy Orchid Chemicals' injectables biz for $400 mn |url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/us-based-hospira-to-buy-orchid-chemicals-injectables-biz-for-400-mn/articleshow/5342003.cms |first1=Mohit |last1=Bhalla |first2=Khomba |last2=Singh |work=[[The Economic Times]] |date=December 16, 2009}}</ref> On November 23, 2015, Pfizer and [[Allergan]] announced a planned $160{{nbsp}}billion merger, in the largest pharmaceutical deal ever and the third largest corporate merger in history. The proposed transaction contemplated that the merged company maintain Allergan's [[Republic of Ireland]] domicile, resulting in the new company being subject to [[corporation tax]] at the relatively low rate of 12.5%.<ref>{{Cite news |title=Pfizer seals $160bn Allergan deal to create drugs giant |url=https://www.bbc.co.uk/news/business-34900344 |work=[[BBC News]] |date=November 23, 2015}}</ref> The deal was to constitute a [[reverse merger]], whereby Allergan acquired Pfizer, with the new company then changing its name to "Pfizer, plc".<ref>{{Cite news |title=Pfizer to buy Allergan in $160 billion deal |url=https://www.reuters.com/article/us-allergan-m-a-pfizer/pfizer-to-buy-allergan-in-160-billion-deal-idUSKBN0TB0UT20151124 |first1=Ransdell |last1=Pierson |first2=Bill |last2=Berkrot |work=[[Reuters]] |date=November 24, 2015}}</ref><ref>{{Cite news |title=Pfizer to Acquire Allergan for $160B |url=https://www.genengnews.com/news/pfizer-to-acquire-allergan-for-160b/ |work=genengnews.com |date=November 23, 2015}}</ref><ref>{{Cite news |first=Cynthia |last=Koons |title=Pfizer and Allergan to Combine With Joint Value of $160 Billion |url=https://www.bloomberg.com/news/articles/2015-11-22/pfizer-allergan-said-to-be-close-to-150-billion-merger |work=[[Bloomberg News]] |date=November 22, 2015 |url-access=limited}}</ref> On April 6, 2016, Pfizer and Allergan terminated the merger agreement after the [[Obama administration]] and the [[United States Department of the Treasury]] introduced new laws intended to limit [[corporate inversion]]s (the extent to which companies could move their headquarters overseas in order to reduce the amount of taxes they pay).<ref>{{Cite news |last=Bray |first=Chad |title=Pfizer and Allergan Call Off Merger After Tax-Rule Changes |url=https://www.nytimes.com/2016/04/07/business/dealbook/pfizer-allergan-merger.html |work=[[The New York Times]] |date=April 6, 2016 |url-access=limited}}</ref><ref>{{Cite news |last1=Humer |first1=Caroline |last2=Banerjee |first2=Ankur |title=Pfizer, Allergan scrap $160 billion deal after U.S. tax rule change |work=[[Reuters]] |url=https://www.reuters.com/article/us-allergan-m-a-pfizer-idUSKCN0X3188 |date=April 6, 2016}}</ref>

In June 2016, the company acquired Anacor Pharmaceuticals for $5.2{{nbsp}}billion, expanding its portfolio in both inflammation and immunology drugs areas.<ref>{{cite press release |url=https://www.businesswire.com/news/home/20160624005299/en/Pfizer-Completes-Acquisition-of-Anacor |title=Pfizer Completes Acquisition of Anacor |publisher=Pfizer |via=[[Business Wire]] |date=June 24, 2016}}</ref><ref>{{Cite news |title=Pfizer to Acquire Anacor Pharmaceuticals for $5.2B |url=https://www.genengnews.com/news/pfizer-to-acquire-anacor-pharmaceuticals-for-5-2b/ |website=genengnews.com |date=May 16, 2016}}</ref> In August 2016, the company made a $40{{nbsp}}million bid for the assets of BIND Therapeutics, which was in [[bankruptcy]].<ref>{{Cite news |title=Pfizer Places High Bid of $40M for BIND Therapeutics |url=https://www.genengnews.com/news/pfizer-places-high-bid-of-40m-for-bind-therapeutics/ |website=genengnews.com |date=July 27, 2016}}</ref> The same month, the company acquired Bamboo Therapeutics for $645{{nbsp}}million, expanding its gene therapy offerings.<ref>{{Cite news |title=Pfizer Acquires Bamboo Therapeutics in a $645M Deal |url=https://www.genengnews.com/news/pfizer-acquires-bamboo-therapeutics-in-a-645m-deal/ |website=genengnews.com |date=August 1, 2016}}</ref> In September 2016, the company acquired cancer drug-maker [[Medivation]] for $14{{nbsp}}billion.<ref>{{Cite news |title=Pfizer to Acquire Medivation for $14B |url=https://www.genengnews.com/news/pfizer-to-acquire-medivation-for-14b/ |website=genengnews.com |date=August 22, 2016}}</ref><ref>{{Cite news |title=Pfizer to buy cancer drug firm Medivation for $14bn |work=[[BBC News]] |url=https://www.bbc.co.uk/news/business-37150531 |date=August 22, 2016}}</ref><ref>{{Cite press release |url=https://www.businesswire.com/news/home/20160928005824/en/ |title=Pfizer Completes Acquisition of Medivation |publisher=OncoImmune |via=[[Business Wire]] |date=September 28, 2016}}</ref> In October 2016, the company licensed the anti-[[CTLA4]] monoclonal antibody, ONC-392, from OncoImmune.<ref>{{Cite news |url=https://www.genengnews.com/topics/drug-discovery/oncoimmune-licenses-onc-392-to-pfizer-for-up-to-250m/ |title=OncoImmune Licenses ONC-392 to Pfizer for Up to $250M |work=genengnews.com |date=October 15, 2016}}</ref><ref>{{cite press release |url=https://www.businesswire.com/news/home/20160915005151/en/OncoImmune-Announces-Option-and-License-Agreement-with-Pfizer-Inc. |title=OncoImmune Announces Option and License Agreement with Pfizer Inc. |publisher=Pfizer |via=[[Business Wire]] |date=September 15, 2016}}</ref> In November 2016, Pfizer funded a $3,435,600 study with the [[CDC Foundation]] to research "screen-and-treat" strategies for [[cryptococcal disease]] in [[Botswana]].<ref name=":4">{{Cite web |date=2021-12-09 |title=CDC Foundation Active Programs October 1, 2020 – September 30, 2021 |url=https://www.cdcfoundation.org/CDCF-ActivePrograms-CDC-FY21?inline |url-status=live |archive-url=https://web.archive.org/web/20220115161004/https://www.cdcfoundation.org/CDCF-ActivePrograms-CDC-FY21?inline |archive-date=2022-01-15 |access-date=2022-08-06 |website=[[CDC Foundation]]}}</ref> In December 2016, Pfizer acquired [[AstraZeneca]]'s small-molecule antibiotics business for $1.575 billion.<ref>{{Cite press release |url=https://www.businesswire.com/news/home/20161222005395/en/Pfizer-Completes-Acquisition-of-Small-Molecule-Anti-Infective-Business-From-AstraZeneca |title=Pfizer Completes Acquisition of Small Molecule Anti-Infective Business From AstraZeneca |publisher=Pfizer |via=[[Business Wire]] |date=December 23, 2016}}</ref><ref>{{Cite news |title=Pfizer Buys AstraZeneca Antibiotics for Up to $1.575B |url=https://www.genengnews.com/topics/drug-discovery/pfizer-buys-astrazeneca-antibiotics-for-up-to-1-575b/ |website=genengnews.com |date=August 24, 2016}}</ref><ref>{{Cite magazine |title=Pfizer grabs AZ antibiotics in $1.5B deal. Pre-split prep or just another sales-boosting buy? |url=https://www.fiercepharma.com/pharma/pfizer-grabs-az-antibiotics-1-5b-deal-pre-split-prep-or-just-another-sales-boosting-buy |first=Tracy |last=Staton |magazine=Fierce Pharma |date=August 24, 2016}}</ref>

In January 2018, Pfizer announced that it would end its work on research into treatments for [[Alzheimer's disease]] and [[Parkinsonism]] (a symptom of [[Parkinson's disease]] and other conditions). The company said about 300 researchers would lose their jobs.<ref>{{Cite news |last=Hiltzik |first=Michael | author-link=Michael Hiltzik |title=Pfizer, pocketing a big tax cut from Trump, will end investment in Alzheimer's and Parkinson's research |url=https://www.latimes.com/business/hiltzik/la-fi-hiltzik-pfizer-20180108-story.html |work=[[Los Angeles Times]] |date=January 8, 2018 |url-access=subscription}}</ref> In July 2018, the [[Food and Drug Administration]] approved [[enzalutamide]], developed by Pfizer and [[Astellas Pharma]] for patients with [[castration]]-resistant [[prostate cancer]].<ref>{{Cite press release |url=https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-enzalutamide-castration-resistant-prostate-cancer |title=FDA approves enzalutamide for castration-resistant prostate cancer |publisher=[[Food and Drug Administration]] |date=July 13, 2018}}</ref> In August 2018, Pfizer signed an agreement with [[BioNTech]] to conduct joint research and development activities regarding [[mRNA]]-based [[influenza vaccine]]s.<ref>{{Cite press release |title=BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza |url=https://biontechse.gcs-web.com/news-releases/news-release-details/biontech-signs-collaboration-agreement-pfizer-develop-mrna-based |publisher=[[BioNTech]] |date=August 16, 2018 |access-date=November 12, 2020 |archive-date=November 24, 2020 |archive-url=https://web.archive.org/web/20201124191744/https://biontechse.gcs-web.com/news-releases/news-release-details/biontech-signs-collaboration-agreement-pfizer-develop-mrna-based/ |url-status=dead }}</ref> In October 2018, effective January 1, 2019, [[Albert Bourla]] was promoted to [[chief executive officer]], succeeding [[Ian Read]], his mentor.<ref>{{Cite news |url=https://www.reuters.com/article/us-pfizer-ceo/pfizer-to-replace-longtime-ceo-read-with-veteran-bourla-idUSKCN1MB29D |title=Pfizer to replace longtime CEO Read with veteran Bourla |first1=Tamara |last1=Mathias |first2=Ankur |last2=Banerjee |date=October 1, 2018 |work=[[Reuters]]}}</ref><ref>{{cite news |last=Maidenberg |first=Micah |title=Pfizer Prepares for CEO Transition With Executive Suite Changes |url=https://www.wsj.com/articles/pfizer-prepares-for-ceo-transition-with-executive-suite-changes-1539095075 |work=[[The Wall Street Journal]] |date=October 9, 2018 |url-access=subscription}}</ref><ref>{{cite news |url=https://www.businessinsider.com/who-is-albert-bourla-next-pfizer-ceo-2018-10 |title=Pfizer's CEO is stepping down after 8 years — meet the man who will be replacing him |last=Ramsey |first=Lydia |work=[[Business Insider]] |date=October 1, 2018 |url-access=subscription}}</ref><ref>{{cite news |last=Jarvis |first=Lisa M. |title=Pfizer unveils CEO succession plan |work=[[Chemical & Engineering News]] |url=https://cen.acs.org/pharmaceuticals/Pfizer-unveils-CEO-succession-plan/96/i40 |date=October 3, 2018}}</ref>
In July 2019, the company acquired Therachon for up to $810{{nbsp}}million, expanding its rare disease portfolio through Therachon's recombinant human fibroblast growth factor receptor 3 compound, aimed at treating conditions such as [[achondroplasia]].<ref>{{Cite news |url=https://www.spglobal.com/marketintelligence/en/news-insights/trending/sWCcSrMgL8UmeCJXuuGp-w2 |title=Pfizer completes acquisition of Therachon to bolster rare disease drug portfolio |first=Ravikash |last=Bakolia |work=[[S&P Global]] |date=July 1, 2019}}</ref> Also in July, Pfizer acquired [[Array Biopharma]] for $10.6{{nbsp}}billion, boosting its oncology pipeline.<ref>{{Cite press release |url=https://www.businesswire.com/news/home/20190730005590/en/Pfizer-Completes-Acquisition-of-Array-Biopharma |title=Pfizer Completes Acquisition of Array Biopharma |publisher=Pfizer |via=[[Business Wire]] |date=July 30, 2019}}</ref> In August 2019, Pfizer merged its consumer health business with that of GlaxoSmithKline, into a [[joint venture]] owned 68% by GlaxoSmithKline and 32% by Pfizer, with plans to make it a [[public company]]. The transaction built on a 2018 transaction where GlaxoSmithKline acquired [[Novartis]]' stake in the GSK-Novartis consumer healthcare joint business.<ref>{{Cite news |url=https://www.bbc.co.uk/news/business-46616713 |title=GlaxoSmithKline and Pfizer merge healthcare arms |work=[[BBC News]] |date=December 19, 2018}}</ref> The transaction followed negotiations with other companies including [[Reckitt Benckiser]],<ref>{{Cite magazine |title=Reckitt Benckiser's still keen on a Pfizer OTC buy. But can it afford one? |url=https://www.fiercepharma.com/pharma/reckitt-benckiser-s-still-keen-a-pfizer-otc-buy-but-can-it-afford-one |magazine=Fierce Pharma |first=Carly |last=Helfand |date=October 16, 2017}}</ref> [[Sanofi]], [[Johnson & Johnson]],<ref>{{Cite magazine |title=Sanofi, J&J could join GlaxoSmithKline, Reckitt in $20B bidding war for Pfizer OTC: report |url=https://www.fiercepharma.com/pharma/sanofi-j-j-could-join-gsk-reckitt-20b-bidding-war-for-pfizer-otc-report |magazine=Fierce Pharma |first=Carly |last=Helfand |date=October 26, 2017}}</ref> and [[Procter & Gamble]].<ref>{{Cite magazine |title=GlaxoSmithKline eyes Pfizer's OTC unit. But will a buy imperil its dividend? |url=https://www.fiercepharma.com/pharma/glaxosmithkline-s-eyeing-pfizer-s-otc-unit-but-will-a-buy-imperil-its-dividend |magazine=Fierce Pharma |first=Carly |last=Helfand |date=October 25, 2017}}</ref> In September 2019, Pfizer initiated a study with the [[CDC Foundation]] to investigate the tracking of [[healthcare-associated infection]]s, scheduled to run through to June 2023.<ref name=":4" /> In December 2019, Pfizer awarded the CDC Foundation a further $1,948,482 to continue its [[cryptococcal disease]] screening and treatment research in nine African countries.<ref name=":4" />